Brand Name

Intelence

Generic Name
Etravirine
View Brand Information
FDA approval date: January 18, 2008
Classification: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Form: Tablet

What is Intelence (Etravirine)?

Etravirine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 infection in antiretroviral treatment-experienced adult patients and pediatric patients 6 years of age and older [see Microbiology (1.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Drug Resistance in HIV Following First-line ART Failure: Insights from a Cross-sectional Study in India.
Drug Resistance in HIV Following First-line ART Failure: Insights from a Cross-sectional Study in India.
Journal: The Journal of the Association of Physicians of India
Published: March 12, 2026
Drug resistance characteristics of rilpivirine in HIV-1-infected patients before starting antiretroviral therapy in nine provinces of China
Drug resistance characteristics of rilpivirine in HIV-1-infected patients before starting antiretroviral therapy in nine provinces of China
Journal: Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
Published: March 01, 2026
Correction: Ly et al. Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation Against Ovarian Cancer Metastasis. Int. J. Mol. Sci. 2022, 23, 944.
Correction: Ly et al. Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation Against Ovarian Cancer Metastasis. Int. J. Mol. Sci. 2022, 23, 944.
Journal: International journal of molecular sciences
Published: January 31, 2026
View All Latest Advances